Install
PR Newswire’s news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- 5,981articles · 30d
- 57+ min agolatest article
- Aug 14, 2026earliest in window
- 92%with images
- 272avg words
- Economy, Business & Finance 2,806
- Finance & Business 2,239
- News 1,499
- Business & Industrial 786
- Science & Technology 652
- Health & Wellness 609
- Medical 563
- Arts, Culture, Entertainment & Media 529
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL - the ZEISS AT LUCIA toric 721P
2+ day, 21+ hour ago (178+ words) Sep 10, 2026, 08:00 ET Launching at ESCRS in London, the world's first bitoric hydrophobic monofocal intraocular lens with a non-constant asphericity profile design expands the ZEISS LUCIA Family to treat cataracts while simultaneously correcting astigmatism. Officially launching at the European Society of…...
HONORING FAMILIES & SAVING CHILDREN'S LIVES: R BABY FOUNDATION & COPE FOUNDATION ANNOUNCE CIRQUETACULAR GALA THIS OCTOBER
3+ day, 20+ hour ago (276+ words) Sep 09, 2026, 09:30 ET October 21 NYC Gala Marks 20 Years of Lifesaving Progress in Pediatric Emergency Care, Honors Families Affected by Loss & Fuels Push for Federal Legislation "No parent should walk into an emergency room and walk out without their child, knowing that…...
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
4+ day, 22+ hour ago (144+ words) Sep 08, 2026, 07:30 ET First OX40 agonist to demonstrate clinical benefit in a randomized study The combination of INBRX-106 and pembrolizumab was generally manageable. The most common treatment-related adverse events were rash, fatigue, and diarrhea, which were predominantly low grade. The Company also…...
Flysound Brings B02 Open-Fit AI Hearing Aid to the U.S.
5+ day, 3+ hour ago (148+ words) Sep 08, 2026, 01:57 ET Rethinking Hearing Aids Beyond the Ear Canal Featuring an open-fit, ear-clip design, B02 helps address common drawbacks of traditional in-ear devices. With hearing aids often worn for more than ten hours a day, comfort is essential to long-term adoption…...
Taiwan's HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures U.S. Patent for Biodegradable Ureteral Stent
5+ day, 7+ hour ago (205+ words) 08 Sep, 2026, 10:00 CST Thai FDA Class 4 Approved Portfolio 2. "Horien" Collagen Matrix A highly biocompatible collagen plug and sheet designed for rapid fluid absorption, local clot stabilization, and superior wound coverage across surgical and dental interventions. 3. "Horien" Extracellular Membrane Our top priority…...
Smartee Expands Pediatric Orthodontic Education Initiatives in Asia Pacific Through Clinical Exchange
1+ week, 4+ day ago (186+ words) 02 Sep, 2026, 10:38 CST SINGAPORE, Aug. 31, 2026 /PRNewswire/ -- Smartee Denti-Technology recently brought together dental professionals for the Smartee Kinder & Teen Workshop, an educational program focused on the clinical assessment and management of growing patients. The program formed part of Smartee's continued clinical education…...
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
1+ week, 4+ day ago (143+ words) 02 Sep, 2026, 09:27 CST Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose…...
Signant Health Unveils Patient-Centered Redesign of TrialMax® eCOA
1+ week, 4+ day ago (401+ words) PR Newswire PHILADELPHIA, Sept. 1, 2026 /PRNewswire/ -- Signant Health, a leading provider of evidence generation solutions for clinical trials, today announced a redesigned patient interface for TrialMax® eCOA. The update is available now for new studies and modernizes the experience patients use…...
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
1+ week, 6+ day ago (321+ words) 30 Aug, 2026, 18:15 CST - Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and…...
New Dx World Summit to Unite the Global Diagnostics Ecosystem in Washington, D.C., August 23-25, 2027
2+ week, 3+ day ago (138+ words) Aug 26, 2026, 15:02 ET "We are thrilled to bring the Next Generation Dx Summit and TRI-CON together into the Dx World Summit." said Iris Goldman, Conference Producer, Dx World Summit. "By teaming up with Diagnostics World News, we're expanding our coverage and…...